Oncologists are definitely not happy about the Centers for Medicare & Medicaid Services’ proposed coverage restrictions for erythropoietin therapies. The agency received more than 1,800 comments on its draft policy, most from oncologists—and virtually all opposed to the changes. (See "Living in a Bipolar World," in this issue Also see "Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1) " - Pink Sheet, 1 July, 2007..)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?